Doxycycline in the management of sexually transmitted infections
Authors:
Open Access
- 22 November 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (3) , 553-563
Abstract
Doxycycline is a second-generation tetracycline, available worldwide for half a century. It is an inexpensive broad-spectrum antimicrobial agent largely used in the management of several bacterial infections, particularly involving intracellular pathogens, as well as in the treatment of acne or for the prophylaxis of malaria. Physicochemical characteristics of doxycycline (liposolubility) allow a high diffusion in the tissues and organs. It has high bioavailability and a long elimination half-life allowing oral administration of one or two daily doses. Over the last decade, the prevalence of bacterial sexually transmitted infections (STIs) (syphilis, chlamydiosis, gonorrhoea and Mycoplasma genitalium infections) has increased in most countries, mainly in MSM, many of whom are infected with HIV. In light of increasing prevalence of resistance towards first-line regimens of some STI agents and recently updated recommendations for STI management, doxycycline appears to be an attractive option compared with other available antibiotics for the treatment of some STIs due to its efficacy, good tolerability and oral administration. More recently, indications for doxycycline in STI prophylaxis have been evaluated. Considering the renewed interest of doxycycline in STI management, this review aims to update the pharmacology of, efficacy of, safety of and resistance to doxycycline in this context of use.Keywords
This publication has 78 references indexed in Scilit:
- The evolution of Mycoplasma genitaliumAnnals of the New York Academy of Sciences, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Re-Evaluating the Treatment of Nongonococcal Urethritis: Emphasizing Emerging Pathogens-A Randomized Clinical TrialClinical Infectious Diseases, 2010
- Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System InfectionsClinical Microbiology Reviews, 2010
- Comparative In Vitro Susceptibilities of Human Mycoplasmas and Ureaplasmas to a New Investigational Ketolide, CEM-101Antimicrobial Agents and Chemotherapy, 2009
- Syphilis and HIV co-infectionEuropean Journal of Internal Medicine, 2009
- Interaction of Doxycycline and WarfarinCornea, 2007
- Safety of doxycycline and minocycline: A systematic reviewClinical Therapeutics, 2005
- Doxycycline induced intracranial hypertensionBMJ, 2003
- Clinical Pharmacokinetics of Doxycycline and MinocyclineClinical Pharmacokinetics, 1988